Humana · Hizentra CIDP · US health-plan appeal rights

Hizentra CIDP denied as not FDA-approved for this use by Humana?

Q: How long do I have to appeal a Humana Hizentra CIDP denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Off-label use is widespread in medicine. If the literature and a recognised specialty-society guideline support the use, plans frequently approve on appeal — especially for cancer, cardiology, and rare disease.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Humana typically requires

Humana's specific coverage criteria for hizentra cidp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: Humana Hizentra (Immune Globulin Subcutaneous) for CIDP Maintenance

The Humana angle on Hizentra CIDP

## Why Humana May Deny Hizentra for CIDP as "Not FDA-Approved"

Humana's "not FDA-approved" denial for Hizentra in CIDP can arise in two distinct situations. First, the plan's system may not yet reflect Hizentra's FDA approval for CIDP maintenance, resulting in a denial based on an outdated policy. Second, the prescribed use may differ from the labeled CIDP indication in some way — for example, a dosing schedule or patient population that falls outside the label — and Humana is treating that variation as an unapproved use.

If the prescribed use falls squarely within Hizentra's FDA-approved CIDP maintenance indication, this denial is straightforwardly rebutted with the current FDA prescribing label. If there is any variation from the labeled use, the appeal must address both the label and the clinical rationale.

## Federal Appeal Rights

ACA §2719 / external review: An "not FDA-approved" denial is subject to mandatory external review under the ACA. The Independent Review Organization must apply current FDA-approval status as part of its review — not just Humana's internal policy language. File within approximately four months of the denial (confirm the exact deadline in your denial letter). Expedited review is available for urgent clinical situations.
ERISA §503: Requires Humana to identify the specific approval-status criterion applied and to conduct a full-and-fair review.

## What to Gather

1. Current FDA prescribing label for Hizentra — highlight the CIDP maintenance indication and confirm the prescribed use matches the label. 2. Diagnosis confirmation — neurology notes and objective testing (nerve conduction studies, EMG, or other evaluations) establishing the CIDP diagnosis. 3. Prescriber medical-necessity letter — confirms the prescribed use is within the FDA-approved indication and references the applicable professional society guideline organization generically. 4. Humana's coverage policy — obtain the current policy and identify the exact language Humana used to classify this as "not approved"; address that language directly. 5. Clinical course documentation — prior treatment history and current disease status supporting the ongoing need for maintenance therapy.

## Criteria-Mapping Structure

| Humana Denial Criterion | Rebuttal Evidence | |---|---| | Each stated basis for the "not approved" determination | FDA label section, prescriber attestation, or clinical note |

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Humana appeals

Other denial reasons for Humana Hizentra CIDP

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.